Sandy Draper
Stock Analyst at Guggenheim
(2.97)
# 1,334
Out of 5,182 analysts
111
Total ratings
60.44%
Success rate
22.18%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $498.34 | -13.31% | 12 | Jul 24, 2024 | |
| EVH Evolent Health | Maintains: Hold | $34 → $28 | $2.25 | +1,144.44% | 10 | May 14, 2024 | |
| IQV IQVIA Holdings | Downgrades: Neutral | n/a | $173.26 | - | 8 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $173.89 | - | 15 | Feb 15, 2024 | |
| GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $2.05 | +387.80% | 4 | Aug 10, 2023 | |
| DOCS Doximity | Downgrades: Neutral | n/a | $22.77 | - | 3 | Aug 9, 2023 | |
| TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $3.12 | -35.90% | 3 | Jun 16, 2023 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $114.19 | +130.32% | 13 | Apr 28, 2023 | |
| AGL agilon health | Maintains: Buy | $525 → $750 | $10.74 | +6,883.24% | 3 | Mar 6, 2023 | |
| HQY HealthEquity | Maintains: Buy | $89 → $94 | $84.63 | +11.07% | 11 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.27 | - | 10 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $21.21 | +140.45% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $207.98 | -37.97% | 2 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $32.25 | +70.54% | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $19.14 | -37.30% | 1 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $6.58 | +659.88% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $8.00 | +712.50% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $1.17 | +2,976.92% | 4 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $173.98 | -4.01% | 3 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.76 | - | 2 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $7.45 | +745.64% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $498.34
Upside: -13.31%
Evolent Health
May 14, 2024
Maintains: Hold
Price Target: $34 → $28
Current: $2.25
Upside: +1,144.44%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $173.26
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $173.89
Upside: -
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $2.05
Upside: +387.80%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $22.77
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $3.12
Upside: -35.90%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $114.19
Upside: +130.32%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $525 → $750
Current: $10.74
Upside: +6,883.24%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $84.63
Upside: +11.07%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $5.27
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $21.21
Upside: +140.45%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $207.98
Upside: -37.97%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $32.25
Upside: +70.54%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $19.14
Upside: -37.30%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $6.58
Upside: +659.88%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $8.00
Upside: +712.50%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $1.17
Upside: +2,976.92%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $173.98
Upside: -4.01%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.76
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $7.45
Upside: +745.64%